Oropouche virus disease: Understanding the emerging threat
Oropouche virus disease is a febrile illness caused by an arbovirus in the Orthobunyavirus genus, primarily transmitted through the bite of infected biting midges and certain mosquitoes. First identified in 1955 in Trinidad and Tobago, the virus has historically caused outbreaks in the Amazon Basin region of South America. However, since late 2023, transmission has expanded to new areas, including several countries and territories in the Caribbean, raising public health concerns.
Symptoms of Oropouche virus disease typically include sudden onset of fever, severe headache, extreme weakness or prostration, joint pain, and muscle pain. Additional symptoms may involve photophobia, dizziness, persistent nausea or vomiting, and low back pain. Fever generally lasts up to five days. While serious complications are uncommon, the infection can progress to aseptic meningitis, usually appearing in the second week of illness and prolonging recovery by several weeks. Up to 60% of patients experience symptom relapses in the weeks following initial recovery.
Transmission occurs primarily through the bite of the biting midge Culicoides paraensis, which maintains a sylvatic cycle involving hosts such as sloths and non-human primates. Certain mosquito species may also contribute to transmission. The virus spreads when these vectors feed on infected animals or humans and then bite susceptible individuals.
Environmental and human-driven factors are influencing the virus’s expanded spread. Increased rainfall and temperatures linked to climate change, combined with deforestation and urbanization, have altered natural habitats and increased contact between vectors, animal reservoirs, and human populations. These changes create conditions favorable for transmission in both rural and urban settings.
As of August 2025, countries with recent or documented human cases of Oropouche virus disease include Bolivia, Brazil, Colombia, Cuba, and others in South America and the Caribbean. Barbados reported its first human cases in 2024, while Cuba documented its first outbreak in May 2024, with cases reported across all provinces that year. Travel-related cases have also been identified, such as a human case in Germany linked to travel to Dominica in 2025.
Prevention focuses on reducing exposure to insect bites. Recommended protective measures include using fine-mesh screens on doors and windows, wearing long-sleeved clothing and long pants, applying insect repellents containing DEET or icaridin, and using bed nets, particularly in areas with active transmission. Public health efforts emphasize vector control, enhanced entomological surveillance, and community education to limit outbreaks.
There is currently no specific antiviral treatment for Oropouche virus disease. Care is supportive, focusing on symptom management such as fever reduction, hydration, and rest. Individuals experiencing symptoms consistent with the disease, especially after travel to affected regions, should seek medical evaluation for proper diagnosis and management.
Ongoing surveillance and research are essential to understand the evolving epidemiology of Oropouche virus, assess the risk of further geographic expansion, and develop effective prevention and control strategies. Public health authorities continue to monitor transmission patterns and update guidance based on the latest evidence.